Bionano Genomics, Inc. Common Stock (BNGO) Stock Price
BNGOStock
$1.25−37.19%52W
Market Cap$14.72M
P/E—
PEG Ratio—
Div yield—
Beta1.73
BNGO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-6.60%
Price vs S&P 500 (4W)-30.37%
VGM Score72.54
BNGO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.67 | -$0.60 | +11.13%(+$0.07) | |
| Q1 2026 | -$0.95 | -$0.75 | +21.35%(+$0.20) | |
| Q4 2025 | -$4.14 | -$0.03 | +99.28%(+$4.11) | |
| Q3 2025 | -$2.34 | -$1.59 | +32.05%(+$0.75) | |
| Q2 2025 | -$2.99 | -$1.97 | +33.97%(+$1.02) |
BNGO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.13
4.13
4.13
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BNGOBionano Genomics, Inc. Common Stock | A | B | C | 0.5x | 27.4% | 47.5% | -106.7% | $1.25 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About Bionano Genomics, Inc. Common Stock
Bionano Genomics develops optical genome mapping systems for detecting structural variations, enabling the discovery of new diagnostics and therapeutic targets in pharmaceutical and clinical research. The company generates revenue from its Saphyr platform, instruments, and consumables, with EMEA as its largest geographic market and operations spanning the Americas, EMEA, and Asia Pacific.